Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifapentine

FDA-approved product (tablet, oral), marketed as Priftin, Rifapentine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifapentine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB05; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifapentine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis95.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifapentine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifapentine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

    NCT00460759 · start 2007-06

    Registered record
    Registry ID
    NCT00460759
    Conditions
    Mycobacterium Tuberculosis
    Interventions
    Moxifloxacin; Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-06
    Completion
    2008-08-24
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Tuberculosis
    InterventionMoxifloxacin; Rifapentine
    PhasePhase 1
    Registry statusTerminated

  • TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection

    NCT00164450 · start 2005-09

    Registered record
    Registry ID
    NCT00164450
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-08
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifapentine
    PhaseNot applicable
    Registry statusCompleted

  • Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

    NCT00023452 · start 2001-06

    Registered record
    Registry ID
    NCT00023452
    Conditions
    Tuberculosis
    Interventions
    RPT + INH once weekly for 3 months given by DOT; Isoniazid (INH) daily for 9 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    2013-09
    Enrolment
    8,053

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRPT + INH once weekly for 3 months given by DOT; Isoniazid (INH) daily for 9 months
    PhasePhase 3
    Registry statusCompleted

  • TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

    NCT00023387 · start 2000-03

    Registered record
    Registry ID
    NCT00023387
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; 25-desacetyl Rifapentine; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-03
    Completion
    2001-05
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; 25-desacetyl Rifapentine; Isoniazid
    PhaseNot applicable
    Registry statusCompleted

  • TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

    NCT00023426 · start 1999-07

    Registered record
    Registry ID
    NCT00023426
    Conditions
    Tuberculosis
    Interventions
    rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-07
    Completion
    2003-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine
    PhasePhase 2
    Registry statusCompleted